WO2015081832A1 - 炔基多臂聚乙二醇衍生物 - Google Patents

炔基多臂聚乙二醇衍生物 Download PDF

Info

Publication number
WO2015081832A1
WO2015081832A1 PCT/CN2014/092738 CN2014092738W WO2015081832A1 WO 2015081832 A1 WO2015081832 A1 WO 2015081832A1 CN 2014092738 W CN2014092738 W CN 2014092738W WO 2015081832 A1 WO2015081832 A1 WO 2015081832A1
Authority
WO
WIPO (PCT)
Prior art keywords
polyethylene glycol
arm polyethylene
alkynyl
integer
terminal
Prior art date
Application number
PCT/CN2014/092738
Other languages
English (en)
French (fr)
Inventor
林美娜
陈晓萌
Original Assignee
北京键凯科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京键凯科技有限公司 filed Critical 北京键凯科技有限公司
Publication of WO2015081832A1 publication Critical patent/WO2015081832A1/zh
Priority to US15/170,905 priority Critical patent/US10280259B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/337—Polymers modified by chemical after-treatment with organic compounds containing other elements
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C08G65/33324—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33306—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/3331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group cyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33334—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33337—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/04—End-capping
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/30—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type branched
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/30—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type branched
    • C08G2650/32—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type branched dendritic or similar
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/60—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing acetylenic group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Definitions

  • the invention relates to a polyethylene glycol active derivative, in particular to a multi-arm polyethylene glycol active derivative having an alkynyl end group and a preparation method thereof.
  • Polyethylene glycol is a widely used polyether polymer compound, which can be applied to many fields such as medicine, health, food, and chemical industry. Polyethylene glycol can be dissolved in water and many solvents, and the polymer has excellent biocompatibility, can be dissolved in the tissue fluid in the body, and can be quickly excreted by the body without any toxic side effects.
  • polyethylene glycol polymer segment is not limited to the terminal hydroxyl group, and the polyethylene glycol active derivative obtained by introducing other functionalized terminal groups such as an amino group, a carboxyl group or an aldehyde group can greatly broaden the polyethylene glycol.
  • the application range has broad application prospects in organic synthesis, peptide synthesis, polymer synthesis, sustained release and controlled release of drugs, and targeted application.
  • Patent document US Pat. No. 5,672,662 describes the preparation of linear polyethylene glycols having a terminal group of propionic acid and butyric acid and their N-hydroxysuccinimide esters.
  • Patent document US Pat. No. 5,643,575 describes a polyethylene glycol derivative having a U-shaped structure.
  • Non-patent literature "Synthesis and solidification of terminal alkynyl polyethylene glycols” Journal of Explosives and Propellants, December 2010, Vol. 33, No. 6 describes a method for synthesizing a terminal alkynyl polyethylene glycol, including Polyethylene glycol 400 and propyne bromide are used as raw materials, and tetrahydrofuran is used as a solvent to obtain a product in the presence of potassium t-butoxide.
  • the polymer prepared by the method is linear polyethylene glycol and introduces at most two. The terminal alkynyl group cannot introduce other reactive groups.
  • Patent WO2011075953A1 describes a novel multi-arm polyethylene glycol having different types of reactive groups formed by polymerizing ethylene oxide from oligomeric pentaerythritol as an initiator, the terminal active group of which is selected from the group consisting of hydroxyl, amino, sulfhydryl and carboxyl groups. And an ester group, an aldehyde group, an acryl group and a maleimide group, wherein the unopened terminal group may be an alkynyl group.
  • the present invention provides an alkynyl-based multi-arm polyethylene glycol active derivative and a process for its preparation.
  • An object of the present invention is to provide an alkynyl-based multi-arm polyethylene glycol active derivative.
  • the multi-arm polyethylene glycol has a plurality of terminal groups and thus has a plurality of functional groups.
  • the introduction point can load a plurality of different active end groups, and solve the problem that the polyethylene glycol terminal alkynyl derivative has poor flexibility and a small application range.
  • Another object of the present invention is to provide a multi-arm polyethylene glycol-alkynyl reactive derivative which can react with other kinds of polymers, is used for gel preparation, and can reduce reaction formation conditions and shorten gel formation. time.
  • Still another object of the present invention is to provide a series of multi-arm polyglycol-alkynyl reactive derivatives having different structures, which solves the problem that the release rate of the active ingredient cannot be achieved when the gel formed by the multi-arm polyethylene glycol-alkynyl reactive derivative is formed. The issue of control.
  • One aspect of the invention provides an alkynyl-based multi-arm polyethylene glycol derivative having the structure of Formula I:
  • Another aspect of the invention provides an alkyne-based multi-arm polyethylene glycol derivative having the structure of formula XVIII:
  • PEG is the same or different -(CH 2 CH 2 O) m -, and m is an integer having an average value of 3-250;
  • l is an integer of ⁇ 1;
  • X 1 , X 2 , X 3 , X 4 are linking groups which may be the same or different and independently selected from the group consisting of C 1-12 alkyl, aralkyl, ester, carbonate a group consisting of an amide group, an amide group, an ether group, and a urethane group;
  • F 1 , F 2 , F 3 , and F 4 are terminal group groups, which may be the same or different, and are independently selected from the group consisting of the following groups:
  • the m average value is preferably an integer of from 18 to 150, and more preferably an integer having an average value of m of from 18 to 75.
  • l is preferably ⁇ 1 and ⁇ 10.
  • An integer, more preferably, l is an integer of ⁇ 1 and ⁇ 6, and particularly preferably l is an integer of ⁇ 1 and ⁇ 4.
  • the l may preferably be 1, 2, 3, 4, 5 or 6.
  • X 1 , X 2 , X 3 , X 4 are a linking group, and more preferably, X 1 , X 2 , X 3 , X 4 are independently selected from -(CH 2 ) i -, -(CH 2 ) i NHCO(CH 2 ) j -, -(CH 2 ) i CONH(CH 2 ) j -, -(CH 2) i NH -, - ( CH 2) i OCOO -, - (CH 2) i OCONH -, - (CH 2) i NHCOO -, - (CH 2) i NHCONH -, - OC (CH 2) i COO -, - (CH 2) i COO -, - (CH 2) i CONH -, - from the group consisting of (CH 2) i COO-
  • i is an integer of from 1 to 10, preferably from 1 to 5, in the formula I or the formula XVIII, X 1 , X 2 , X 3 , X 4 An integer, more preferably an integer from 1 to 3, in a particular embodiment of the invention, the i is 1, 2, 3, 4 or 5.
  • X 1 , X 2 , X 3 , X 4 , j is an integer of from 1 to 10, preferably 1 An integer of 5, more preferably an integer of 1-3, in a particular embodiment of the invention, said j is 1, 2, 3, 4 or 5.
  • the F 1 , F 2 , F 3 , F 4 may be at least two In another embodiment of the present invention, at least three of F 1 , F 2 , F 3 , and F 4 are In another embodiment of the present invention, F 1 , F 2 , F 3 , and F 4 are all
  • the F 1 , F 2 , F 4 may be at least two In another embodiment of the invention, F 1 , F 2 , and F 4 are both
  • the multi-arm polyethylene glycol derivative of the present invention in the formula I or formula XVIII, has a molecular weight of from 1000 to 80,000 Da, which is preferred in the practice of the invention.
  • the multi-arm polyethylene glycol has a molecular weight of 3000-20000 Da.
  • the multi-arm polyethylene glycol has a molecular weight of 3000-10000 Da, in the present invention.
  • the multi-arm polyethylene glycol may have a molecular weight of 3000 Da, 5000 Da, 10000 Da, 20000 Da.
  • the multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol-alkynyl derivative having the structure of Formula II below:
  • X 1 , X 2 , X 3 , X 4 are independently selected from -(CH 2 ) i -, -(CH 2 ) i NHCO(CH 2 ) j -, -(CH 2 ) i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol monoalkynyl-polyacid derivative having the structure of Formula III below:
  • the k is an integer of 1-10.
  • the alkynyl multi-arm polyethylene glycol monoalkynyl-polyacid derivative of the formula III structure is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of -5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyalkynyl-polyacid derivative having the structure of Formula IV below:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-polyacid derivative of the structure of Formula IV is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO (CH 2 ) j -; i is an integer of 1-10, preferably an integer of 1-5, more preferably 1, 2, 3, 4 or 5; j is an integer of 1-10, preferably 1-5 The integer is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyacetylenic-monoacid derivative having the structure of the following formula V:
  • the k is an integer of 1-10.
  • the multi-arm polyethylene glycol polyalkynyl-monoacid derivative of the structure of the formula V is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO (CH 2 ) j -; i is an integer of 1-10, preferably an integer of 1-5, more preferably 1, 2, 3, 4 or 5; j is an integer of 1-10, preferably 1-5 The integer is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol monoalkynyl-polyacid active NHS ester derivative having the structure of Formula VI:
  • the k is an integer of 1-10.
  • the multi-arm polyethylene glycol monoalkynyl-polyacid reactive NHS ester derivative of the structure of Formula VI is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 i NHCO(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably An integer of 1-5, more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyalkynyl-polyacid active NHS ester derivative having the structure of Formula VII below:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-polyacid reactive NHS ester derivative of the formula VII is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 i NHCO(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably An integer of 1-5, more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyalkynyl-monoacid active NHS ester derivative having the structure of Formula VIII below:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-monoacid derivative of the structure of the formula VIII is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO (CH 2 ) j -; i is an integer of 1-10, preferably an integer of 1-5, more preferably 1, 2, 3, 4 or 5; j is an integer of 1-10, preferably 1-5 The integer is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol monoalkynyl-polyacid active MAL derivative having the structure of Formula IX below:
  • the k is an integer of 1-10.
  • the multi-arm polyethylene glycol monoalkynyl-polyacid reactive MAL derivative of the structure of Formula IX is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of -5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyacetylenic-polyacid active MAL derivative having the structure of the general formula X:
  • the k is an integer of 1-10.
  • the multi-arm polyethylene glycol polyalkynyl-polyacid reactive MAL derivative of the formula X structure is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of -5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyacetylenic-monoacid active MAL derivative having the structure of Formula XI below:
  • the k is an integer of 1-10.
  • the multi-arm polyethylene glycol polyalkynyl-monoacid reactive MAL derivative of the structure of Formula XI is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i NHCO(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of -5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol monoalkynyl-polyamine derivative having the structure of the general formula XII:
  • the k is an integer of 1-10.
  • the multi-arm polyethylene glycol monoalkynyl-polyamine derivative of the formula XII is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of 5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyalkynyl-polyamine derivative having the structure of the general formula XIII:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-polyamine derivative of the formula XIII is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of 5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyalkynyl-monoamine derivative having the structure of the general formula XIV:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-monoamine derivative of the formula XIII is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of 5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol monoalkynyl-polyamine reactive MAL derivative having the structure of the general formula XV:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol monoalkynyl-polyamine reactive MAL derivative of the formula XV structure is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably An integer of 1-5, more preferably 1, 2, 3, 4 or 5; k is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-arm polyethylene glycol polyalkynyl-polyamine-based active MAL derivative having the following formula XVI:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-polyamine reactive MAL derivative of the formula XVI is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably An integer of 1-5, more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • the alkynyl multi-arm polyethylene glycol derivative is a multi-structure having the following formula XVII Arm polyethylene glycol polyalkynyl-monoamine-based active MAL derivative:
  • the k is an integer of 1-10.
  • the multiarm polyethylene glycol polyalkynyl-monoamine derivative of the formula XVII is preferred, wherein X 1 is -(CH 2 ) i - or -(CH 2 ) i CONH(CH 2 ) j -; i is an integer from 1 to 10, preferably an integer from 1 to 5, more preferably 1, 2, 3, 4 or 5; j is an integer from 1 to 10, preferably 1 An integer of 5 is more preferably 1, 2, 3, 4 or 5; k is preferably an integer of 1 to 5, more preferably 1, 2, 3, 4 or 5.
  • Another aspect of the present invention provides a method for preparing an alkyne-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol in a solvent, adding sodium hydride at room temperature, and adding bromopropyne and potassium iodide.
  • the reaction, after separation, is more than polyethylene glycol-propyne.
  • the present invention provides a process for preparing an alkynyl-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol-terminated acetic acid and N-hydroxysuccinimide (NHS) in a solvent. After adding N,N'-dicyclohexylcarbodiimide (DCC), the reaction was carried out by adding propargylamine to separate the arms of polyethylene glycol-propyneacetamide.
  • DCC N,N'-dicyclohexylcarbodiimide
  • Another aspect of the present invention provides a method for preparing an alkynyl-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol-terminated hydroxyl-terminated methyl acetate in a solvent, and adding sodium hydride. After the reaction at room temperature, bromopropyne and potassium iodide are added to obtain a multi-arm polyethylene glycol-propyne-methyl acetate; after the polyarm polyethylene glycol-propyne-methyl acetate is hydrolyzed, polyethylene glycol is obtained. Propyne-acetic acid derivatives.
  • another aspect of the present invention provides a method for preparing an alkyne-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol-terminated hydroxyl-terminated methyl acetate in a solvent, After adding sodium hydride at room temperature, the reaction of adding bromopropyne and potassium iodide to obtain multi-arm polyethylene glycol-propyne-methyl acetate; hydrolyzing the multi-arm polyethylene glycol-propyne-methyl acetate to obtain polyethylene a diol-propyne-acetic acid derivative; dissolving a polyethylene glycol-propyne-acetic acid derivative in a solvent, adding N-hydroxysuccinimide (NHS) and N,N'-dicyclohexylcarbodiimide Amine (DCC), the reaction is much more than polyethylene glycol-propyne-acetic acid NHS ester.
  • N-hydroxysuccinimide NHS
  • DCC N,N'
  • another aspect of the present invention provides a method for preparing an alkyne-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol-terminated hydroxyl-terminated methyl acetate in a solvent, After adding sodium hydride at room temperature, the reaction of adding bromopropyne and potassium iodide to obtain multi-arm polyethylene glycol-propyne-methyl acetate; hydrolyzing the multi-arm polyethylene glycol-propyne-methyl acetate to obtain polyethylene a diol-propyne-acetic acid derivative; the polyethylene glycol-propyne-acetic acid derivative is dissolved in a solvent and added N-hydroxysuccinimide (NHS) and N,N'-dicyclohexylcarbodiimide (DCC), after the reaction, additional maleimide ethylenediamine reaction, multi-arm polyethylene glycol-end Propyl-terminated acetic acid MAL ester.
  • NPS N-
  • Another aspect of the present invention provides a method for preparing an alkyne-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol-terminal acetic acid-terminal ethylamine in a solvent, and adding triethylamine.
  • di-tert-butyl dicarbonate (Boc 2 O), reacting with more arms polyethylene glycol-acetic acid-Boc amide; after the reaction, multi-arm polyethylene glycol-acetic acid-Boc amide and N-hydroxysuccinimide ( NHS) 0.086g is dissolved in a solvent, and after adding N,N'-dicyclohexylcarbodiimide (DCC), the reaction is carried out by adding propargylamine to obtain a multi-arm polyethylene glycol-alkynyl-Boc amide; The multi-arm polyethylene glycol-alkynyl-Boc amide is dissolved in a solvent, and trifluoroacetic acid is added to react, and the arms are polyethylene glycol-terminal alkynyl-terminal ethylamine.
  • NHS N-hydroxysuccinimide
  • DCC N,N'-dicyclohexylcarbodiimide
  • another aspect of the present invention provides a method for preparing an alkynyl-based multi-arm polyethylene glycol derivative, which comprises dissolving a multi-arm polyethylene glycol-terminal acetic acid-terminal ethylamine in a solvent, and adding three Ethylamine and di-tert-butyl dicarbonate (Boc 2 O), reacting more arms with polyethylene glycol-acetic acid-Boc amide; after reaction, multi-arm polyethylene glycol-acetic acid-Boc amide and N-hydroxysuccinyl amide
  • the amine (NHS) is dissolved in a solvent, and after adding N,N'-dicyclohexylcarbodiimide (DCC), the reaction is carried out by adding propargylamine to obtain a multi-arm polyethylene glycol-alkynyl-Boc amide; Multi-arm polyethylene glycol-alkynyl-Boc amide is dissolved in a solvent, trifluoroacetic acid
  • the terminal methyl acetate, the multi-arm polyethylene glycol-terminal acetic acid-terminal ethylamine is commercially available or can be prepared by the method of the patent CN102108119A.
  • the solvent may be selected from a suitable solvent known in the art, and is selected from the group consisting of methanol, ethanol, chloroform, dichloromethane, acetone, diethyl ether and acetic acid. Ethyl ester and the like.
  • the alkynyl multi-arm polyethylene glycol derivative of the invention can be used for combination with proteins, peptides and pharmaceutically active small molecules to improve targeting and drug efficacy and reduce toxicity.
  • the protein, peptide, and pharmaceutically active small molecule include, but are not limited to, analgesic and anti-inflammatory agents, antacids, anthelmintics, antiarrhythmic agents, antibacterial agents, anticoagulant (blood) agents, antidepressants , antidiabetic agents, antidiarrheal agents, antiepileptic drugs, antifungal agents, anti-gout drugs, antihypertensive drugs, antimalarials, anti-migraine drugs, antimuscarinic agents, antineoplastic agents and immunosuppressants, antigens Insecticides, antirheumatic drugs, antithyroid agents, antiviral agents, anti-anxiety agents, sedatives, eye drops and tranquilizers, beta-blockers, cardiac contractions, corticosteroids, antit
  • the alkynyl multi-arm polyethylene glycol derivative of the present invention can be combined with a protein, a peptide and a pharmaceutically active small molecule, as described in the patent CN102108119A, through a combination of a terminal group and a drug molecule, preferably by- COOH or Combined with proteins, peptides, and pharmaceutically active small molecules.
  • the alkynyl multi-arm polyethylene glycol derivative of the present invention has a plurality of branches, and further has a plurality of functional group introduction points and can support a plurality of active end groups.
  • the multi-arm polyethylene glycol alkynyl derivative provided by the invention can obviously increase the loading ratio of the alkynyl active end group, and can also load other different active end groups, so that the multi-arm polyethylene glycol derivative has Stronger application flexibility and larger application range have better application prospects in organic synthesis, drug synthesis and medical devices.
  • the multi-armed polyethylene glycol alkynyl derivative provided by the present invention is capable of reacting with other polymers, particularly polyethylene glycol azide derivatives, to form a gel, and is derived from a multi-arm polyethylene glycol alkynyl group.
  • the change in molecular weight and number of branches in the material enables control of the release rate of the active ingredient.
  • the above four-arm polyethylene glycol propyne-monoacetate methyl ester 5.0g was dissolved in 50ml of degassed water, the pH was adjusted to 12.0 with 0.5N sodium hydroxide aqueous solution, and the reaction was carried out at room temperature for 2-2.5 hours, and the pH was adjusted with 1N hydrochloric acid aqueous solution. To 2-3, 6.0 g of sodium chloride was added, and the mixture was extracted three times with 50 ml of dichloromethane. The organic phase was combined, dried over anhydrous sodium sulfate, filtered, and concentrated to viscous at 45 ° C. Four arms of polyethylene glycol-propyne-monoacetic acid were obtained in 3.6 g.
  • Example 8 Preparation of eight-arm polyethylene glycol (10000 Da)-monoalkynyl-heptaacetic acid
  • Example 12 Preparation of octapolyethylene glycol (20000 Da)-heptynyl-monoethylamine MAL
  • Example 13 Preparation of a four-arm polyethylene glycol-alkynyl group (molecular weight 5000) gel and its in vitro release experiment
  • the above gel was placed in a dialysis bag (throttle molecular weight 5000), washed three times with 20 ml of water, until the aqueous solution was detected by high performance liquid chromatography without absorption of ultraviolet light, placed in a glass bottle, 20 ml of water was added, and the thermostat was stirred at 40 ° C. Shake in the middle. Samples were taken at 30 min, 2 h, and 4 h, and an aqueous solution of irinotecan-glycine hydrochloride of 0.0025 g/ml was used as a reference sample, and the release amount of the gel at each time point was measured by high performance liquid chromatography.
  • the release ratio of irinotecan-glycine was: 0.5% 21%, 2 hours 36%, 4 hours 42%.
  • Example 14 Preparation of a four-arm polyethylene glycol-alkynyl group (molecular weight 10000) gel and its in vitro release experiment
  • a four-arm polyethylene glycol-alkynyl group (molecular weight: 10,000) 0.25 g, a polyethylene glycol-azido derivative (molecular weight: 10,000) 0.25 g, and irinotecan-glycine hydrochloride 0.05 g were dissolved in water 5 ml. 0.004 g of sodium ascorbate and 0.002 g of copper acetate were added, and the mixture was stirred at room temperature for 1 hour to form a gel.
  • the above gel was placed in a dialysis bag (throttle molecular weight 5000), washed three times with 20 ml of water, until the aqueous solution was detected by high performance liquid chromatography without absorption of ultraviolet light, placed in a glass bottle, 20 ml of water was added, and the thermostat was stirred at 40 ° C. Shake in the middle. Samples were taken at 30 min, 2 h, and 4 h, and an aqueous solution of irinotecan-glycine hydrochloride of 0.0025 g/ml was used as a reference sample, and the release amount of the gel at each time point was measured by high performance liquid chromatography.
  • the release ratio of irinotecan-glycine was 0.55% 35%, 2 hours 54%, and 4 hours 69%.
  • Example 15 Preparation of an 8-arm polyethylene glycol-alkynyl group (molecular weight 10000) gel and its in vitro release experiment
  • An eight-arm polyethylene glycol-alkynyl group (molecular weight: 10,000) 0.25 g, a polyethylene glycol-azide derivative (molecular weight: 10,000) 0.25 g, and irinotecan-glycine hydrochloride 0.05 g were dissolved in water 5 ml. 0.008 g of sodium ascorbate and 0.004 g of copper acetate were added, and the mixture was stirred at room temperature for 10 minutes to form a gel.
  • the above gel was placed in a dialysis bag (throttle molecular weight 5000), washed three times with 20 ml of water, until the aqueous solution was detected by high performance liquid chromatography without absorption of ultraviolet light, placed in a glass bottle, 20 ml of water was added, and the thermostat was stirred at 40 ° C. Shake in the middle. Samples were taken at 30 min, 2 h, and 4 h, and an aqueous solution of irinotecan-glycine hydrochloride of 0.0025 g/ml was used as a reference sample, and the release amount of the gel at each time point was measured by high performance liquid chromatography.
  • the release ratio of irinotecan-glycine was: 24 hours 24%, 2 hours 48%, 4 hours 60%.
  • the molecular weight and the number of polydiethanol branches can be used to influence or control the condensation.
  • the formation time of the gum, the smaller the molecular weight, the more the number of branches, the shorter the gel formation time, and the increased number of branches of polyethylene glycol can increase the gel formation rate more effectively.
  • the molecular weight and the number of branches have a significant effect on the release time in vitro. Therefore, the preparation of different multi-arm polyethylene glycol-alkynyl derivatives can also be used to control the drug release process.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供一种具有通式I或通式X VIII的结构的炔基多臂聚乙二醇衍生物。在该衍生物中，X1, X2, X3, X4是连接基团，F1, F2, F3, F4为端基基团，所述端基基团可以是相同的也可以是不同的，选自：羟基，羧基，酯基，氨基，炔基等，并且所述端基基团中至少有一个为炔基，PEG为相同或不同的-(CH2CH2O)m-，m为3-250的整数，l为≥1的整数。多臂聚乙二醇具有多个分支，可以负载多个活性端基，同时还可以负载多种不同的活性端基，使所得到的多臂聚乙二醇衍生物具有更强的应用灵活性和更大的应用范围，在有机合成、药物合成及医疗器械等方面均有较好的应用前景。

Description

炔基多臂聚乙二醇衍生物 技术领域
本发明涉及一种聚乙二醇活性衍生物，尤其是涉及一种具有炔基端基的多臂聚乙二醇活性衍生物及其制备方法。
背景技术
聚乙二醇是一种用途极为广泛的聚醚高分子化合物，它可应用于医药、卫生、食品、化工等众多领域。聚乙二醇能够溶解于水和许多溶剂中，且该聚合物具有优异的生物相容性，在体内能溶于组织液中，能被机体迅速排出体外而不产生任何毒副作用。
在聚乙二醇的应用中，端基起着决定性的作用，不同端基的聚乙二醇具有不同的用途。聚乙二醇高分子链段不仅局限于端羟基，通过引入其他功能化端基，如氨基、羧基、醛基等所得到的聚乙二醇活性衍生物，可以极大地拓宽聚乙二醇的应用范围，使它在有机合成、多肽合成、高分子合成及药物的缓释控释、靶向施药等多方面均具有广阔的应用前景。
聚乙二醇活性衍生物在很多文献中均有报道。
专利文献US5672662描述了制备端基为丙酸和丁酸的线形聚乙二醇以及它们的N-羟基丁二酰亚胺酯。
专利文献US5643575描述了一种U形结构的聚乙二醇衍生物。
非专利文献“端炔基聚乙二醇的合成及固化”(火***学报，2010年12月，第33卷第6期)描述了一种端炔基聚乙二醇的合成方法，包括以聚乙二醇400和丙炔溴为原料，四氢呋喃为溶剂，在催化剂叔丁醇钾存在下反应得到产物，然而该方法制备得到的聚合物中为直链聚乙二醇，并且最多引入两个端炔基，无法引入其它活性基团。
专利WO2011075953A1描述一种由寡聚季戊四醇作为引发剂聚合环氧乙烷形成的新型的具有不同类型活性基团的多臂聚乙二醇，其端基活性集团选自：羟基、氨基、巯基、羧基、酯基、醛基、丙烯酸基和马来亚酰胺基，其未公开端基活性基团可以为炔基。
为克服现有技术中的缺陷，本发明提供了一种炔基多臂聚乙二醇活性衍生物及其制备方法。
发明内容
本发明一个目的是提供一种炔基多臂聚乙二醇活性衍生物，与直链型聚乙二醇相比，多臂聚乙二醇具有多个端基，进而具有多个功能基团的引入点、可以负载多个不同的活性端基，解决聚乙二醇端基炔基衍生物使用灵活性不佳、应用范围较小的问题。
本发明另一个目的是提供一种多臂聚乙二醇-炔基活性衍生物，能够与其它种类的聚合物反应，用于凝胶的制备，并能够降低反应形成的条件、缩短凝胶形成的时间。
本发明还一个目的是提供一系列不同结构的多臂聚乙二醇-炔基活性衍生物，解决了多臂聚乙二醇-炔基活性衍生物形成的凝胶时无法对活性成分释放速度进行控制的问题。
本发明的一方面提供了一种炔基多臂聚乙二醇活性衍生物，所述的多臂聚乙二醇衍生物具有通式Ⅰ的结构：
Figure PCTCN2014092738-appb-000001
本发明的另一方面提供了一种炔基多臂聚乙二醇衍生物，所述的多臂聚乙二醇衍生物具有通式ⅩⅧ的结构：
Figure PCTCN2014092738-appb-000002
其中：
PEG为相同或不同的-(CH2CH2O)m-，m是平均值为3-250的整数；
l为≧1的整数；
X1，X2，X3，X4是连接基团，可以相同或者不同，独立地选自由以下基团组成的组选自C1-12烷基、芳烷基、酯基、碳酸酯基、酰胺基、酰胺酯基、醚基、氨基甲酸酯基组成的组；
F1，F2，F3，F4是端基基团，可以相同或者不同，独立地选自由以下基团组成的组：
-NH2、-COOH、-OCH3、
Figure PCTCN2014092738-appb-000003
并且F1，F2，F3，F4至少有一个为
Figure PCTCN2014092738-appb-000004
在本发明所述的炔基多臂聚乙二醇衍生物通式Ⅰ或通式ⅩⅧ中，m平均值优选为18-150的整数，更优选为m平均值为18-75的整数。
在本发明所述的炔基多臂聚乙二醇衍生物通式Ⅰ或通式ⅩⅧ中，l优选为≥1且≤10的 整数，更优选l为≥1且≤6的整数，尤其优选l为≥1且≤4的整数，在本发明的具体实施方式中，所述的l可以优选为1、2、3、4、5或6。
在本发明所述的炔基多臂聚乙二醇衍生物通式Ⅰ或通式ⅩⅧ中，X1，X2，X3，X4是连接基团，更为优选的，X1，X2，X3，X4独立地选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-、-(CH2)iNH-、-(CH2)iOCOO-、-(CH2)iOCONH-、-(CH2)iNHCOO-、-(CH2)iNHCONH-、-OC(CH2)iCOO-、-(CH2)iCOO-、-(CH2)iCONH-、-(CH2)iCOO-组成的组；最为优选的，X1，X2，X3，X4独立地选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-组成的组。
在本发明所述的炔基多臂聚乙二醇衍生物通式Ⅰ或通式ⅩⅧ，X1，X2，X3，X4中i为1-10的整数，优选为1-5的整数，更优选为1-3的整数，在本发明的具体实施方式中，所述的i为1、2、3、4或5。
在本发明所述的端基炔基多臂聚乙二醇衍生物通式Ⅰ或通式ⅩⅧ，X1，X2，X3，X4中j为1-10的整数，优选为1-5的整数，更优选为1-3的整数，在本发明的具体实施方式中，所述的j为1、2、3、4或5。
在本发明所述的端基炔基多臂聚乙二醇衍生物通式Ⅰ中，所述的F1，F2，F3，F4可以至少两个为
Figure PCTCN2014092738-appb-000005
在本发明的另一实施方式中，F1，F2，F3，F4至少三个为
Figure PCTCN2014092738-appb-000006
在本发明的另一实施方式中，F1，F2，F3，F4均为
Figure PCTCN2014092738-appb-000007
在本发明所述的端基炔基多臂聚乙二醇衍生物通式ⅩⅧ中，所述的F1，F2，F4可以至少两个为
Figure PCTCN2014092738-appb-000008
在本发明的另一实施方式中，F1，F2，F4均为
Figure PCTCN2014092738-appb-000009
在本发明所述的端基炔基多臂聚乙二醇衍生物通式Ⅰ或通式ⅩⅧ中，所述多臂聚乙二醇衍生物的分子量为1000-80000Da，在本发明优选的实施方案中，所述的多臂聚乙二醇的分子量为3000-20000Da，在本发明的更为优选的实施方案中，所述的多臂聚乙二醇的分子量为3000-10000Da，在本发明的最优选的实施方案中，所述的多臂聚乙二醇的分子量可以为3000Da、5000Da、10000Da、20000Da。
在一个具体实施方案中，所述的多臂聚乙二醇衍生物是具有以下通式Ⅱ结构的多臂聚乙二醇-炔基衍生物：
Figure PCTCN2014092738-appb-000010
在一个具体实施方案中，所述通式Ⅱ结构的多臂聚乙二醇-炔基衍生物中，X1，X2，X3，X4独立地选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅲ结构的多臂聚乙二醇单炔基-多酸衍生物：
Figure PCTCN2014092738-appb-000011
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅲ结构的炔基多臂聚乙二醇单炔基-多酸衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅳ结构的多臂聚乙二醇多炔基-多酸衍生物：
Figure PCTCN2014092738-appb-000012
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅳ结构的多臂聚乙二醇多炔基-多酸衍生物优选的， 其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅴ结构的多臂聚乙二醇多炔基-单酸衍生物：
Figure PCTCN2014092738-appb-000013
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅴ结构的多臂聚乙二醇多炔基-单酸衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅵ结构的多臂聚乙二醇单炔基-多酸活性NHS酯衍生物：
Figure PCTCN2014092738-appb-000014
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅵ结构的多臂聚乙二醇单炔基-多酸活性NHS酯衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅶ结构的多臂聚乙二醇多炔基-多酸活性NHS酯衍生物：
Figure PCTCN2014092738-appb-000015
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅶ结构的多臂聚乙二醇多炔基-多酸活性NHS酯衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅷ结构的多臂聚乙二醇多炔基-单酸活性NHS酯衍生物：
Figure PCTCN2014092738-appb-000016
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅷ结构的多臂聚乙二醇多炔基-单酸衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅸ结构的多臂聚乙二醇单炔基-多酸活性MAL衍生物：
Figure PCTCN2014092738-appb-000017
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅸ结构的多臂聚乙二醇单炔基-多酸活性MAL衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅹ结构的多臂聚乙二醇多炔基-多酸活性MAL衍生物：
Figure PCTCN2014092738-appb-000018
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅹ结构的多臂聚乙二醇多炔基-多酸活性MAL衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅺ结构的多臂聚乙二醇多炔基-单酸活性MAL衍生物：
Figure PCTCN2014092738-appb-000019
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅺ结构的多臂聚乙二醇多炔基-单酸活性MAL衍生物优选的，其中X1是-(CH2)i-或-(CH2)iNHCO(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式Ⅻ结构的多臂聚乙二醇单炔基-多胺基衍生物：
Figure PCTCN2014092738-appb-000020
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式Ⅻ结构的多臂聚乙二醇单炔基-多胺基衍生物优选的，其中X1是-(CH2)i-或-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式ⅩⅢ结构的多臂聚乙二醇多炔基-多胺基衍生物：
Figure PCTCN2014092738-appb-000021
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式ⅩⅢ结构的多臂聚乙二醇多炔基-多胺基衍生物优选的，其中X1是-(CH2)i-或-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式ⅩⅣ结构的多臂聚乙二醇多炔基-单胺基衍生物：
Figure PCTCN2014092738-appb-000022
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式ⅩⅢ结构的多臂聚乙二醇多炔基-单胺基衍生物优选的，其中X1是-(CH2)i-或-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式ⅩⅤ结构的多臂聚乙二醇单炔基-多胺基活性MAL衍生物：
Figure PCTCN2014092738-appb-000023
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式ⅩⅤ结构的多臂聚乙二醇单炔基-多胺基活性MAL衍生物优选的，其中X1是-(CH2)i-或-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式ⅩⅥ结构的多臂聚乙二醇多炔基-多胺基活性MAL衍生物：
Figure PCTCN2014092738-appb-000024
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式ⅩⅥ结构的多臂聚乙二醇多炔基-多胺基活性MAL衍生物优选的，其中X1是-(CH2)i-或-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
在一个具体实施方案中，所述炔基多臂聚乙二醇衍生物是具有以下通式ⅩⅦ结构的多 臂聚乙二醇多炔基-单胺基活性MAL衍生物：
Figure PCTCN2014092738-appb-000025
其中所述PEG、l、X1同通式Ⅰ或通式ⅤⅢ中定义，所述k为1-10的整数。
在一个具体实施方案中，所述通式ⅩⅦ结构的多臂聚乙二醇多炔基-单胺基衍生物优选的，其中X1是-(CH2)i-或-(CH2)iCONH(CH2)j-；i为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；j为1-10的整数，优选为1-5的整数，更优选为为1、2、3、4或5；k优选为1-5的整数，更优选为为1、2、3、4或5。
本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，分离后得多臂聚乙二醇-丙炔。
本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇-端基乙酸和N-羟基琥珀酰亚胺(NHS)溶于溶剂中，加入N,N'-二环己基碳二亚胺(DCC)反应后，加入炔丙胺反应分离后得多臂聚乙二醇-丙炔乙酰胺。
本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇-端基羟基-端基乙酸甲酯溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，得到多臂聚乙二醇-丙炔-乙酸甲酯；将多臂聚乙二醇-丙炔-乙酸甲酯水解后，得到聚乙二醇-丙炔-乙酸衍生物。
进一步的，本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇-端基羟基-端基乙酸甲酯溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，得到多臂聚乙二醇-丙炔-乙酸甲酯；将多臂聚乙二醇-丙炔-乙酸甲酯水解后，得到聚乙二醇-丙炔-乙酸衍生物；将聚乙二醇-丙炔-乙酸衍生物溶于溶剂中，加入N-羟基琥珀酰亚胺(NHS)和N,N'-二环己基碳二亚胺(DCC)，反应得多臂聚乙二醇-丙炔-乙酸NHS酯。
进一步的，本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇-端基羟基-端基乙酸甲酯溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，得到多臂聚乙二醇-丙炔-乙酸甲酯；将多臂聚乙二醇-丙炔-乙酸甲酯水解后，得到聚乙二醇-丙炔-乙酸衍生物；将聚乙二醇-丙炔-乙酸衍生物溶于溶剂中，加入 N-羟基琥珀酰亚胺(NHS)和N,N'-二环己基碳二亚胺(DCC)，反应后，再加入马来酰亚乙二胺反应，得多臂聚乙二醇-端基丙炔-端基乙酸MAL酯。
本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇-端基乙酸-端基乙胺溶于溶剂中，加入三乙胺和二碳酸二叔丁酯(Boc2O)，反应得多臂聚乙二醇-乙酸-Boc酰胺；反应后将多臂聚乙二醇-乙酸-Boc酰胺和N-羟基琥珀酰亚胺(NHS)0.086g溶于溶剂中，加入N,N'-二环己基碳二亚胺(DCC)反应后，再加入炔丙胺反应，得到多臂聚乙二醇-炔基-Boc酰胺；将上述多臂聚乙二醇-炔基-Boc酰胺溶于溶剂中，加入三氟乙酸反应，得多臂聚乙二醇-端基炔基-端基乙胺。
进一步，本发明另一方面还提供了一种炔基多臂聚乙二醇衍生物的制备方法，包括将多臂聚乙二醇-端基乙酸-端基乙胺溶于溶剂中，加入三乙胺和二碳酸二叔丁酯(Boc2O)，反应得多臂聚乙二醇-乙酸-Boc酰胺；反应后将多臂聚乙二醇-乙酸-Boc酰胺和N-羟基琥珀酰亚胺(NHS)溶于溶剂中，加入N,N'-二环己基碳二亚胺(DCC)反应后，再加入炔丙胺反应，得到多臂聚乙二醇-炔基-Boc酰胺；将上述多臂聚乙二醇-炔基-Boc酰胺溶于溶剂中，加入三氟乙酸反应，得多臂聚乙二醇-端基炔基-端基乙胺；将多臂聚乙二醇-端基炔基-端基乙胺溶于溶剂中，加入3-马来酰亚胺基丙酸羟基琥珀酰亚胺酯反应，得到多臂聚乙二醇-端基炔基-端基乙胺MAL。
本发明所述炔基多臂聚乙二醇衍生物的制备方法中，反应物多臂聚乙二醇、多臂聚乙二醇-端基乙酸、多臂聚乙二醇-端基羟基-端基乙酸甲酯、多臂聚乙二醇-端基乙酸-端基乙胺可由市售获得，或者通过专利CN102108119A中的方法制备得到。
本发明所述炔基多臂聚乙二醇衍生物的制备方法中，所述的溶剂可以使用本领域所述熟知适宜溶剂，选自甲醇、乙醇、氯仿、二氯甲烷、丙酮、***、乙酸乙酯等。
本发明所述的炔基多臂聚乙二醇衍生物可以用于与蛋白质、肽、药物活性小分子相结合，提高靶向性和药物疗效，降低毒性。所述的蛋白质、肽、药物活性小分子包括但不限于：镇痛剂和消炎剂、抗酸剂、驱虫药、抗心律不齐药、抗菌剂、抗凝(血)剂、抗抑郁剂、抗糖尿病剂、止泻剂、抗癫痫药、防真菌剂、抗痛风药、抗高血压药、抗疟药、抗偏头痛药、抗毒蕈碱剂、抗瘤剂和免疫抑制剂、抗原虫药、抗风湿药、抗甲状腺剂、抗病毒剂、抗焦虑剂、镇静剂、安眼药和安定药、β-受体阻断剂、心脏收缩剂、皮质类甾醇、镇咳剂、细胞毒性剂、减充血剂、利尿剂、酶、抗帕金森氏症药、胃肠道药、组胺受体拮抗剂、油脂调节剂、局部麻醉剂、神经肌肉阻断剂、硝酸酯和抗心绞痛药、营养剂、麻醉性镇痛剂、口服疫苗、蛋白、肽和重组药物、性激素和避孕药、杀***剂、和刺激剂。
本发明所述的炔基多臂聚乙二醇衍生物与蛋白质、肽、药物活性小分子结合方式，可以如专利CN102108119A所描述，通过其端基与药物分子所形成的结合物，优选通过-COOH或
Figure PCTCN2014092738-appb-000026
与蛋白质、肽、药物活性小分子相结合。
与直链型聚乙二醇相比，本发明所述的炔基多臂聚乙二醇衍生物具有多个分支，进而具有多个功能基团的引入点、可以负载多个活性端基。
同时，本发明提供的多臂聚乙二醇炔基衍生物能够明显提高炔基活性端基的负载率，还可以负载其他不同的活性端基，使所述多臂聚乙二醇衍生物具有更强的应用灵活性和更大的应用范围，在有机合成、药物合成及医疗器械等方面均有较好的应用前景。
另外，本发明提供的多臂聚乙二醇炔基衍生物能够与其它聚合物，特别是聚乙二醇叠氮衍生物发生反应形成凝胶，并且通过对多臂聚乙二醇炔基衍生物中分子量、分支数的改变能够实现对活性成分的释放速率控制。
具体实施方式
下面结合实施例描述本发明的衍生物及其制备方法，所述实施例不意图限制本发明，本发明的保护范围由本申请的权利要求书限定。
实施例1：四臂聚乙二醇(10000Da)-丙炔的制备
Figure PCTCN2014092738-appb-000027
将四臂聚乙二醇(10000Da)10.0g溶于四氢呋喃150ml中，氮气保护下降温至0℃，加入氢化钠0.48g，室温反应0.5小时，加入溴丙炔(80％的甲苯溶液)22.4ml，加入碘化钾0.09g，避光加热回流2小时，降温，加入水100ml，旋出四氢呋喃，用二氯甲烷萃取三次，无水硫酸钠干燥，过滤，浓缩，45℃浓缩至黏稠，加入***100ml沉淀，过滤收集沉淀真空干燥。得到四臂聚乙二醇-丙炔8.7g。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000028
4H)
实施例2：八臂聚乙二醇(20000Da)-丙炔乙酰胺的制备
Figure PCTCN2014092738-appb-000029
将八臂聚乙二醇(20000Da)-乙酸10.0g和N-羟基琥珀酰亚胺(NHS)0.69g溶于二氯甲烷100ml中，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)1.32g，反应4h，加入炔丙胺0.9ml，避光反应过夜，过滤，40℃浓缩，用异丙醇150ml加热溶解冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得八臂聚乙二醇-丙炔乙酰胺9.0g。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000030
4H),7.66(t,CONH,4H)
实施例3：四臂聚乙二醇(5000Da)-炔基-单乙酸的制备
Figure PCTCN2014092738-appb-000031
将四臂聚乙二醇(5000Da)羟基-单乙酸甲酯10.0g溶于四氢呋喃150ml中，氮气保护下降温至0℃，加入氢化钠0.72g，室温反应0.5小时，加入溴丙炔(80％的甲苯溶液)33.6ml，加入碘化钾0.135g，避光加热回流2小时，降温，加入水100ml，旋出四氢呋喃，用二氯甲烷萃取三次，无水硫酸钠干燥，过滤，浓缩，45℃浓缩至黏稠，加入***100ml沉淀，过滤收集沉淀真空干燥。得到四臂聚乙二醇丙炔-单乙酸甲酯8.2g。
将上述四臂聚乙二醇丙炔-单乙酸甲酯5.0g溶于50ml脱气水中，用0.5N氢氧化钠水溶液调节PH为12.0，室温下反应2-2.5小时，用1N盐酸水溶液调解PH为2-3，加入氯化钠6.0g，用二氯甲烷50ml萃取三次，合并有机相，无水硫酸钠干燥，过滤，45℃浓缩至黏稠，加入***75ml沉淀，过滤收集沉淀真空干燥。得到四臂聚乙二醇-丙炔-单乙酸3.6g。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000032
4H),4.01(s,CH2COOH,8H)
实施例4：四臂聚乙二醇(5000Da)-炔基-单乙酸活性NHS酯的制备
Figure PCTCN2014092738-appb-000033
称取四臂聚乙二醇(5000Da)-丙炔-单乙酸1.0g和N-羟基琥珀酰亚胺(NHS)0.0276g，用二氯甲烷10ml溶解，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)0.0536g，密闭反应过夜，过滤，40℃浓缩至干，用异丙醇20ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得四臂聚乙二醇-丙炔-单乙酸NHS酯。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000034
3H),4.6(s,CH2CO,2H),2.8(s,CH2ring,4H)
实施例5：四臂聚乙二醇(5000Da)-炔基-单乙酸MAL的制备
Figure PCTCN2014092738-appb-000035
称取四臂聚乙二醇(5000Da)-丙炔-单乙酸1.0g和N-羟基琥珀酰亚胺(NHS)0.035g，用二氯甲烷10ml溶解，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)0.066g溶于二氯甲烷10ml中，反应4h，加入马来酰亚乙二胺0.115g，避光反应过夜，40℃浓缩至干，用异丙醇20ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得四臂聚乙二醇-炔基-单乙酸MAL。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000036
3H),2.32(t,CH2N,2H),7.0(s,CH ring,2H)
实施例6：四臂聚乙二醇(20000Da)-二炔基-二乙胺的制备
Figure PCTCN2014092738-appb-000037
将四臂聚乙二醇-二乙酸-二乙胺基(分子量为20000)10.0g溶于二氯甲烷100ml中， 加入三乙胺0.15ml，搅拌10分钟，加入二碳酸二叔丁酯(Boc2O)0.3ml，室温反应过夜，45℃浓缩，用100ml***沉淀，过滤，真空干燥得四臂聚乙二醇-二乙酸-二Boc酰胺9.7g。
将四臂聚乙二醇-二乙酸-二Boc酰胺5g和N-羟基琥珀酰亚胺(NHS)0.086g，用二氯甲烷50ml溶解，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)0.165g，反应4h，加入炔丙胺0.11ml，密闭反应过夜，过滤，40℃浓缩至干，用异丙醇75ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得四臂聚乙二醇-二炔基-二Boc酰胺4.3g。
将上述四臂聚乙二醇-二炔基-二Boc酰胺3.0g溶于二氯甲烷21ml中，加入三氟乙酸9ml，反应3小时，45℃浓缩，60ml***沉淀，过滤，真空干燥得四臂聚乙二醇-二炔基-二乙胺2.3g。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000038
2H),3.0(m,CH2N,4H)
实施例7：四臂聚乙二醇(20000Da)-二炔基-二乙胺MAL的制备
Figure PCTCN2014092738-appb-000039
将四臂聚乙二醇(20000Da)-二炔基-二乙胺1.0g溶于二氯甲烷10ml中，加入3-马来酰亚胺基丙酸羟基琥珀酰亚胺酯0.035g，避光反应过夜，40℃浓缩至干，用异丙醇20ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得四臂聚乙二醇-二炔基-二乙胺MAL。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000040
2H),2.32(t,CH2N,4H),7.0(s,CH ring,4H)
实施例8：八臂聚乙二醇(10000Da)-单炔基–七乙酸的制备
Figure PCTCN2014092738-appb-000041
将4-炔丁酸14.7g溶于二氯甲烷100ml中，加入N-羟基琥珀酰亚胺(NHS)1.89g，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)3.75g，室温密闭反应过夜，将八臂聚 乙二醇(10000Da)-单羟基-七乙酸甲酯10g溶于二氯甲烷100ml中，将上述溶液加入反应瓶中，反应4h，过滤，40℃浓缩至干，用异丙醇200ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得到八臂聚乙二醇-炔基-七乙酸甲酯8.3g。
将上述八臂聚乙二醇-炔基-七乙酸甲酯5.0g溶于50ml脱气水中，用0.5N氢氧化钠水溶液调节PH为12.0，室温下反应2-2.5小时，用1N盐酸水溶液调解PH为2-3，加入氯化钠6.0g，用二氯甲烷50ml萃取三次，合并有机相，无水硫酸钠干燥，过滤，45℃浓缩至黏稠，加入***75ml沉淀，过滤收集沉淀真空干燥。得到八臂聚乙二醇-炔基-七乙酸3.3g。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000042
1H),4.01(s,CH2COOH,14H)
实施例9：八臂聚乙二醇(10000Da)-炔基-七乙酸NHS酯的制备
Figure PCTCN2014092738-appb-000043
将八臂聚乙二醇(10000Da)-单炔基–七乙酸1.0g和N-羟基琥珀酰亚胺(NHS)0.12g，用二氯甲烷10ml溶解，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)0.23g，密闭反应过夜，过滤，40℃浓缩至干，用异丙醇20ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得八臂聚乙二醇-单炔基-七乙酸NHS酯。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000044
1H),4.6(s,CH2CO,14H),2.8(s,CH2ring,28H)实施例10：八臂聚乙二醇(10000Da)-炔基-七乙酸MAL的制备
Figure PCTCN2014092738-appb-000045
称取八臂聚乙二醇(10000Da)-单炔基–七乙酸1.0g和N-羟基琥珀酰亚胺(NHS)0.12g，用二氯甲烷10ml溶解，氮气保护下，加入N,N'-二环己基碳二亚胺(DCC)0.23g，反应4h，加入马来酰亚乙二胺0.35g，避光反应过夜，40℃浓缩至干，用异丙醇20ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得八臂聚乙二醇(10000Da)-单炔基–七乙酸MAL。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000046
1H),2.32(t,CH2N,14H),7.0(s,CH ring,14H)实施例11：八臂聚乙二醇(20000Da)-七炔基-单乙胺的制备
Figure PCTCN2014092738-appb-000047
将八臂聚乙二醇(20000Da)-七羟基-单乙胺10.0g溶于二氯甲烷100ml中，加入三乙胺0.077ml，搅拌10分钟，加入二碳酸二叔丁酯(Boc2O)0.15ml，室温反应过夜，45℃浓缩，用100ml***沉淀，过滤，真空干燥得八臂聚乙二醇(20000Da)-七羟基-单Boc酰胺9.5g。
将八臂聚乙二醇(20000Da)-七羟基-单Boc酰胺5.0g溶于四氢呋喃100ml中，氮气保护下降温至0℃，加入氢化钠0.024g，室温反应0.5小时，加入溴丙炔(80％的甲苯溶液)1.12ml，加入碘化钾0.0045g，避光加热回流2小时，降温，加入水50ml，旋出四氢呋喃，用二氯甲烷萃取三次，无水硫酸钠干燥，过滤，浓缩，45℃浓缩至黏稠，加入***100ml沉淀，过滤收集沉淀真空干燥。得到八臂聚乙二醇(20000Da)-七丙炔-单Boc酰胺3.9g。
将八臂聚乙二醇(20000Da)-七丙炔-单Boc酰胺3.0g溶于二氯甲烷21ml中，加入三氟乙酸9ml，反应3小时，45℃浓缩，60ml***沉淀，过滤，真空干燥得八臂聚乙二醇(20000Da)-七炔基-单乙胺2.3g。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000048
7H),3.0(m,CH2N,2H)
实施例12：八臂聚乙二醇(20000Da)-七炔基-单乙胺MAL的制备
Figure PCTCN2014092738-appb-000049
将八臂聚乙二醇(20000Da)-七炔基-单乙胺1.0g溶于二氯甲烷10ml中，加入3-马来酰亚胺基丙酸羟基琥珀酰亚胺酯0.017g，避光反应过夜，40℃浓缩至干，用异丙醇20ml加热溶解后冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得八臂聚乙二醇(20000Da)-七炔基-单乙胺MAL。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000050
7H),2.32(t,CH2N,2H),7.0(s,CH ring,2H)
实施例13：四臂聚乙二醇-炔基(分子量为5000)凝胶的制备及其体外释药实验
将四臂聚乙二醇-炔基(分子量为5000)0.25g、聚乙二醇-叠氮衍生物(分子量为5000)0.25g以及伊立替康-甘氨酸盐酸盐0.05g溶于水5ml，加入抗坏血酸钠0.008g、醋酸铜0.004g，室温下搅拌25分钟形成凝胶。
将以上凝胶放入透析袋(节流分子量5000)中，以水20ml洗涤三次，至水溶液用高效液相色谱检测紫外无吸收，放入玻璃瓶中，加入水20ml，于40℃恒温振荡器中振摇。在30min、2h、4h分别取样，以0.0025g/ml的伊立替康-甘氨酸盐酸盐的水溶液作为参比样品，高效液相色谱测定凝胶在各时间点的释放量。
伊立替康-甘氨酸的释放比例为：0.5小时21％，2小时36％，4小时42％。
实施例14：四臂聚乙二醇-炔基(分子量为10000)凝胶的制备及其体外释药实验
将四臂聚乙二醇-炔基(分子量为10000)0.25g、聚乙二醇-叠氮衍生物(分子量为10000)0.25g以及伊立替康-甘氨酸盐酸盐0.05g溶于水5ml，加入抗坏血酸钠0.004g、醋酸铜0.002g，室温下搅拌1小时形成凝胶。
将以上凝胶放入透析袋(节流分子量5000)中，以水20ml洗涤三次，至水溶液用高效液相色谱检测紫外无吸收，放入玻璃瓶中，加入水20ml，于40℃恒温振荡器中振摇。在30min、2h、4h分别取样，以0.0025g/ml的伊立替康-甘氨酸盐酸盐的水溶液作为参比样品，高效液相色谱测定凝胶在各时间点的释放量。
伊立替康-甘氨酸的释放比例为：0.5小时35％，2小时54％，4小时69％。
实施例15：八臂聚乙二醇-炔基(分子量为10000)凝胶的制备及其体外释药实验
将八臂聚乙二醇-炔基(分子量为10000)0.25g、聚乙二醇-叠氮衍生物(分子量为10000)0.25g以及伊立替康-甘氨酸盐酸盐0.05g溶于水5ml，加入抗坏血酸钠0.008g、醋酸铜0.004g，室温下搅拌10分钟形成凝胶。
将以上凝胶放入透析袋(节流分子量5000)中，以水20ml洗涤三次，至水溶液用高效液相色谱检测紫外无吸收，放入玻璃瓶中，加入水20ml，于40℃恒温振荡器中振摇。在30min、2h、4h分别取样，以0.0025g/ml的伊立替康-甘氨酸盐酸盐的水溶液作为参比样品，高效液相色谱测定凝胶在各时间点的释放量。
伊立替康-甘氨酸的释放比例为：0.5小时24％，2小时48％，4小时60％。
由实施例13-15可见，在多臂聚乙二醇-炔基衍生物与其它聚乙二醇衍生物形成凝胶的制备中，分子量与聚二乙醇分支数均可以用来影响或控制凝胶的形成时间，分子量越小，分支数越多，凝胶的形成时间越短，而且增加聚乙二醇的分支数量可以更有效地提高凝胶的形成速度。同时，分子量与分支数对体外释药时间同样有显著地影响，因此，制备不同的多臂聚乙二醇-炔基衍生物也可以用于控制药物缓释过程。
实施例16：四臂聚乙二醇-三炔基-多巴胺及凝胶的制备
Figure PCTCN2014092738-appb-000051
将四臂聚乙二醇-丙炔-单乙酸NHS活性酯(分子量为5000)3.0g溶于二氯甲烷30ml中，加入多巴胺0.12g、三乙胺0.11ml，避光室温反应过夜，40℃浓缩，用异丙醇60ml加热溶解，冰水浴沉淀，过滤，异丙醇洗涤滤饼2次，真空干燥得四臂聚乙二醇-三丙炔-多巴胺。
1H-NMR(DMSO)δ：3.08(s,
Figure PCTCN2014092738-appb-000052
3H),6.4(m,ring,1H),6.6(m,ring,2H),8.6(s,OH,1H),8.7(s,OH,1H)
将四臂聚乙二醇-三丙炔-多巴胺(分子量为5000)0.33g、聚乙二醇-叠氮衍生物(分子量为5000)0.25g溶于水6ml，加入抗坏血酸钠0.008g、醋酸铜0.004g，室温下搅拌30分钟形成凝胶。

Claims (17)

  1. 一种具有通式Ⅰ或通式ⅩⅧ结构的炔基多臂聚乙二醇活性衍生物：
    Figure PCTCN2014092738-appb-100001
    其中：
    PEG为相同或不同的-(CH2CH2O)m-，m是平均值为3-250的整数；
    l为≧1的整数；
    X1，X2，X3，X4是连接基团，可以相同或者不同，独立地选自由以下基团组成的组：C1-12烷基、芳烷基、酯基、碳酸酯基、酰胺基、酰胺酯基、醚基、氨基甲酸酯基；
    F1，F2，F3，F4是端基基团，可以相同或者不同，独立地选自由以下基团组成的组：
    -NH2、-COOH、-OCH3、
    Figure PCTCN2014092738-appb-100002
    -C≡CH。
    并且F1，F2，F3，F4至少有一个为-C≡CH。
  2. 如权利要求1所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的l为1、2、3、4、5或6。
  3. 如权利要求1-2任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的X1，X2，X3，X4独立地选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-、-(CH2)iNH-、-(CH2)iOCOO-、-(CH2)iOCONH-、-(CH2)iNHCOO-、-(CH2)iNHCONH-、-OC(CH2)iCOO-、-(CH2)iCOO-、-(CH2)iCONH-、-(CH2)iCOO-组成的组；X1，X2，X3，X4中i为1-10的整数；X1，X2，X3，X4中j为1-10的整数。
  4. 如权利要求1-3任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，X1，X2，X3，X4独立地选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-组成的组；X1， X2，X3，X4中i为1、2、3、4或5；X1，X2，X3，X4中j为1、2、3、4或5。
  5. 如权利要求1-4任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的端基炔基多臂聚乙二醇活性衍生物通式Ⅰ中，所述的F1，F2，F3，F4至少两个为-C≡CH。
  6. 如权利要求1-4任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的端基炔基多臂聚乙二醇活性衍生物通式Ⅰ中，F1，F2，F3，F4至少三个为-C≡CH。
  7. 如权利要求1-4任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的端基炔基多臂聚乙二醇活性衍生物通式Ⅰ中，F1，F2，F3，F4均为-C≡CH。
  8. 如权利要求1-4任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的端基炔基多臂聚乙二醇活性衍生物通式ⅩⅧ中，所述的F1，F2，F4至少两个为-C≡CH。
  9. 如权利要求1-4任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的端基炔基多臂聚乙二醇活性衍生物通式ⅩⅧ中，所述的F1，F2，F4均为-C≡CH。
  10. 权利要求1-9任意一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述炔基多臂聚乙二醇活性衍生物的分子量为1000-80000Da。
  11. 权利要求1-9任意一项所述的炔基多臂聚乙二醇衍生物，其特征在于，所述的炔基多臂聚乙二醇活性衍生物的分子量为3000-20000Da。
  12. 一种炔基多臂聚乙二醇活性衍生物，其特征在于，具有如下通式结构：
    Figure PCTCN2014092738-appb-100003
    Figure PCTCN2014092738-appb-100004
    Figure PCTCN2014092738-appb-100005
    Figure PCTCN2014092738-appb-100006
    其中：
    PEG为相同或不同的-(CH2CH2O)m-，m是平均值为3-250的整数；
    l为≧1的整数；
    X1选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-、-(CH2)iNH-、-(CH2)iOCOO-、-(CH2)iOCONH-、-(CH2)iNHCOO-、-(CH2)iNHCONH-、-OC(CH2)iCOO-、-(CH2)iCOO-、-(CH2)iCONH-、-(CH2)iCOO-组成的组；X1中i为1-10的整数，j为1-10的整数；
    k为1-10的整数。
  13. 如权利要求12所述的炔基多臂聚乙二醇活性衍生物，其特征在于，X1选自-(CH2)i-、-(CH2)iNHCO(CH2)j-、-(CH2)iCONH(CH2)j-组成的组；X1中i为1、2、3、4或5，j为1、2、3、4或5。
  14. 如权利要求12-13任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述的端基炔基多臂聚乙二醇衍生物中k为1、2、3、4或5。
  15. 权利要求12-14任一项所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述 炔基多臂聚乙二醇活性衍生物的分子量为1000-80000Da。
  16. 权利要求15所述的炔基多臂聚乙二醇活性衍生物，其特征在于，所述炔基多臂聚乙二醇活性衍生物的分子量为3000-20000Da。
  17. 权利要求1所述的一种具有通式Ⅰ或通式ⅩⅧ的结构的炔基多臂聚乙二醇活性衍生物的制备方法，其特征在于，包括：
    将多臂聚乙二醇溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，分离后得多臂聚乙二醇-丙炔；
    或者，将多臂聚乙二醇-端基乙酸和N-羟基琥珀酰亚胺溶于溶剂中，加入N,N'-二环己基碳二亚胺反应后，加入炔丙胺反应分离后得多臂聚乙二醇-丙炔乙酰胺；
    或者，将多臂聚乙二醇-端基羟基-端基乙酸甲酯溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，得到多臂聚乙二醇-丙炔-乙酸甲酯；将多臂聚乙二醇-丙炔-乙酸甲酯水解后，得到聚乙二醇-丙炔-乙酸衍生物；
    或者，将多臂聚乙二醇-端基羟基-端基乙酸甲酯溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，得到多臂聚乙二醇-丙炔-乙酸甲酯；将多臂聚乙二醇-丙炔-乙酸甲酯水解后，得到聚乙二醇-丙炔-乙酸衍生物；将聚乙二醇-丙炔-乙酸衍生物溶于溶剂中，加入N-羟基琥珀酰亚胺和N,N'-二环己基碳二亚胺，反应得多臂聚乙二醇-丙炔-乙酸NHS酯；
    或者，将多臂聚乙二醇-端基羟基-端基乙酸甲酯溶于溶剂中，加入氢化钠室温反应后，加入溴丙炔和碘化钾反应，得到多臂聚乙二醇-丙炔-乙酸甲酯；将多臂聚乙二醇-丙炔-乙酸甲酯水解后，得到聚乙二醇-丙炔-乙酸衍生物；将聚乙二醇-丙炔-乙酸衍生物溶于溶剂中，加入N-羟基琥珀酰亚胺和N,N'-二环己基碳二亚胺，反应后，再加入马来酰亚乙二胺反应，得多臂聚乙二醇-端基丙炔-端基乙酸MAL酯；
    或者，将多臂聚乙二醇-端基乙酸-端基乙胺溶于溶剂中，加入三乙胺和二碳酸二叔丁酯，反应得多臂聚乙二醇-乙酸-Boc酰胺；反应后将多臂聚乙二醇-乙酸-Boc酰胺和N-羟基琥珀酰亚胺溶于溶剂中，加入N,N'-二环己基碳二亚胺反应后，再加入炔丙胺反应，得到多臂聚乙二醇-炔基-Boc酰胺；将上述多臂聚乙二醇-炔基-Boc酰胺溶于溶剂中，加入三氟乙酸反应，得多臂聚乙二醇-端基炔基-端基乙胺；
    或者，将多臂聚乙二醇-端基乙酸-端基乙胺溶于溶剂中，加入三乙胺和二碳酸二叔丁酯，反应得多臂聚乙二醇-乙酸-Boc酰胺；反应后将多臂聚乙二醇-乙酸-Boc酰胺和N-羟基琥珀酰亚胺溶于溶剂中，加入N,N'-二环己基碳二亚胺反应后，再加入炔丙胺反应，得 到多臂聚乙二醇-炔基-Boc酰胺；将上述多臂聚乙二醇-炔基-Boc酰胺溶于溶剂中，加入三氟乙酸反应，得多臂聚乙二醇-端基炔基-端基乙胺；将多臂聚乙二醇-端基炔基-端基乙胺溶于溶剂中，加入3-马来酰亚胺基丙酸羟基琥珀酰亚胺酯反应，得到多臂聚乙二醇-端基炔基-端基乙胺MAL。
PCT/CN2014/092738 2013-12-02 2014-12-02 炔基多臂聚乙二醇衍生物 WO2015081832A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/170,905 US10280259B2 (en) 2013-12-02 2016-06-01 Alkynyl multi-arm polyethylene glycol derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310632776.0 2013-12-02
CN201310632776 2013-12-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/170,905 Continuation US10280259B2 (en) 2013-12-02 2016-06-01 Alkynyl multi-arm polyethylene glycol derivative

Publications (1)

Publication Number Publication Date
WO2015081832A1 true WO2015081832A1 (zh) 2015-06-11

Family

ID=52895093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/092738 WO2015081832A1 (zh) 2013-12-02 2014-12-02 炔基多臂聚乙二醇衍生物

Country Status (3)

Country Link
US (1) US10280259B2 (zh)
CN (2) CN104448296B (zh)
WO (1) WO2015081832A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5820815B2 (ja) 2009-12-15 2015-11-24 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ インプラントおよび生体分解性基準マーカー
CN106146325B (zh) * 2015-04-24 2019-01-29 北京键凯科技股份有限公司 一种y型多缩乙二醇衍生物及其制备方法
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107469089B (zh) 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
CN108653746B (zh) * 2017-03-29 2021-04-27 北京键凯科技股份有限公司 一种多载药点、高载药配基药物偶联物
CN109206610B (zh) 2017-06-30 2020-06-30 北京键凯科技股份有限公司 一种适用于点击化学反应的多臂多爪聚乙二醇衍生物
WO2019001550A1 (zh) * 2017-06-30 2019-01-03 北京键凯科技股份有限公司 一种适用于点击化学反应的多臂多爪聚乙二醇衍生物
CN109608633A (zh) * 2018-11-09 2019-04-12 北京诺康达医药科技股份有限公司 一种新型的特异性多臂聚乙二醇衍生物及其制备方法
CN110954707B (zh) * 2019-07-04 2022-12-13 北京九强生物技术股份有限公司 丙戊酸衍生物及其在免疫检测中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040058A2 (en) * 2000-11-14 2002-05-23 Shearwater Corporation Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
CN101549169A (zh) * 2008-04-01 2009-10-07 Tyco医疗健康集团 使用点击化学法形成的生物粘合剂组合物
US20090324742A1 (en) * 2006-09-08 2009-12-31 Sonke Svenson Peham dendrimers as excipients
CN101724144A (zh) * 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
CN102108119A (zh) * 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040058A2 (en) * 2000-11-14 2002-05-23 Shearwater Corporation Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
US20090324742A1 (en) * 2006-09-08 2009-12-31 Sonke Svenson Peham dendrimers as excipients
CN101549169A (zh) * 2008-04-01 2009-10-07 Tyco医疗健康集团 使用点击化学法形成的生物粘合剂组合物
CN101724144A (zh) * 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
CN102108119A (zh) * 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶

Also Published As

Publication number Publication date
CN107759783A (zh) 2018-03-06
CN104448296B (zh) 2018-01-05
US10280259B2 (en) 2019-05-07
CN104448296A (zh) 2015-03-25
US20160271267A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
WO2015081832A1 (zh) 炔基多臂聚乙二醇衍生物
WO2015081831A1 (zh) 多臂聚乙二醇-叠氮衍生物
AU749321B2 (en) Polymeric derivatives of camptothecins
TWI655213B (zh) 自我組織化肽衍生物的製造方法
WO2015081830A1 (zh) 多臂聚乙二醇硬脂酸衍生物和油酸衍生物
CN109608633A (zh) 一种新型的特异性多臂聚乙二醇衍生物及其制备方法
JP2010520333A (ja) 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
CN108623802B (zh) 一种功能性聚氨基酸衍生物及其制备方法和应用
WO2003074586A1 (fr) Compose d'oligopeptide de polycarboxyle/de polymere hydrophile et medicaments, composition medicale renfermant le compose susmentionne et utilisation dudit compose dans des medicaments
WO2017157188A1 (zh) 一种多臂聚乙二醇及其活性衍生物
RU2254330C2 (ru) Кислотно-аддитивные нитратные соли соединений и фармацевтическая композиция
CN112029091B (zh) 一种pH/还原双重响应性嵌段共聚物PEG-b-PAsp-g-CPA
CN104356196A (zh) 基于寡肽的还原敏感脂质衍生物及其在药物递送中的应用
CN105085927B (zh) 一种三元嵌段共聚物及其制备方法和利用其制成的滴眼液
WO2020233289A1 (zh) 托拉塞米磷酸酯类前药、其制备方法及组合物
CN111454457A (zh) 一种以树状分子为侧链的手性肽类抗菌聚合物及其制备方法
US20050220753A1 (en) Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them
JP2020055850A (ja) 終末糖化産物（ａｇｅ）前駆体の捕捉剤
WO2019001549A1 (zh) 一种多臂单一分子量聚乙二醇及其活性衍生物及其制备和应用
CN108359052A (zh) 一种藤黄酸-叶酸-hpma高分子聚合物及其制备方法和应用
CN112341367A (zh) 氧化还原响应的小分子凝胶化合物及其制备方法和该化合物的小分子凝胶及其应用
WO2021060443A1 (ja) 非対称分岐型分解性ポリエチレングリコール誘導体
CN115887376B (zh) 一种去氢骆驼蓬碱修饰药、制备方法及应用
CN108295030A (zh) 蟾毒灵胶束纳米制剂及其制备方法
CN116947936A (zh) 一种靶向线粒体的鱼藤醇-地喹氯铵-透明质酸化合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14867686

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14867686

Country of ref document: EP

Kind code of ref document: A1